Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong
- PMID: 15284314
- DOI: 10.1093/pubmed/fdh138
Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong
Abstract
Background: To assess the cost-effectiveness of alternative cervical cancer screening strategies to inform the design and implementation of a government-sponsored population-based screening programme in Hong Kong.
Methods: Cost-effectiveness analysis using a computer-based model of cervical carcinogenesis was performed. Strategies included no screening, opportunistic screening (status quo), organized screening using either conventional or liquid-based cytology conducted at different frequencies. The main outcome measures were cancer incidence reduction, years of life saved (YLS), lifetime costs and incremental cost-effectiveness ratios. Data were from local hospitals and laboratories, clinical trials, prospective studies and other published literature.
Results: Compared with no screening, a simulation of the current situation of opportunistic screening using cervical cytology produced a nearly 40 per cent reduction in the lifetime risk of cervical cancer. However, with organized screening every 3, 4 and 5 years, corresponding reductions with conventional (and liquid-based) cytology were 90.4 (92.9), 86.8 (90.2) and 83.2 per cent (87.3 per cent) compared with no screening. For all cytology-based screening strategies, opportunistic screening was more costly and less effective than an organized programme of screening every 3, 4 and 5 years. Every 3-, 4- and 5-year screening cost $12,300, $7100 and $800 per YLS, each compared with the next best alternative.
Conclusions: Compared with the status quo of opportunistic screening, adopting a policy of organized, mass cervical screening in Hong Kong can substantially increase benefits and reduce costs.
Similar articles
-
The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.Transplantation. 2009 Apr 15;87(7):1078-91. doi: 10.1097/TP.0b013e31819d32eb. Transplantation. 2009. PMID: 19352131
-
Cost-effectiveness of cervical-cancer screening in five developing countries.N Engl J Med. 2005 Nov 17;353(20):2158-68. doi: 10.1056/NEJMsa044278. N Engl J Med. 2005. PMID: 16291985
-
Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.Obstet Gynecol. 2006 May;107(5):997-1005. doi: 10.1097/01.AOG.0000210529.70226.0a. Obstet Gynecol. 2006. PMID: 16648402
-
[Population screening for uterine cervix cancer: the negative effects of insufficient knowledge as to what is normal and abnormal].Ned Tijdschr Geneeskd. 2002 Aug 24;146(34):1569-71. Ned Tijdschr Geneeskd. 2002. PMID: 12224477 Review. Dutch.
-
[Cancer of the cervix uteri: analysis of the cost-benefit and efficacy of opportunistic screening versus organized screening].Rev Med Liege. 1998 May;53(5):305-7. Rev Med Liege. 1998. PMID: 9689888 Review. French.
Cited by
-
Estimating the cost of cervical cancer screening in five developing countries.Cost Eff Resour Alloc. 2006 Aug 3;4:13. doi: 10.1186/1478-7547-4-13. Cost Eff Resour Alloc. 2006. PMID: 16887041 Free PMC article.
-
See-and-treat approaches to cervical cancer prevention for HIV-infected women.Curr HIV/AIDS Rep. 2011 Sep;8(3):192-9. doi: 10.1007/s11904-011-0084-6. Curr HIV/AIDS Rep. 2011. PMID: 21706187 Free PMC article.
-
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.Popul Health Metr. 2007 Oct 29;5:11. doi: 10.1186/1478-7954-5-11. Popul Health Metr. 2007. PMID: 17967185 Free PMC article.
-
Health economic evaluations of medical devices in the People's Republic of China: A systematic literature review.Clinicoecon Outcomes Res. 2015 Apr 9;7:195-204. doi: 10.2147/CEOR.S78752. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 25914551 Free PMC article.
-
Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.Br J Cancer. 2010 Dec 7;103(12):1773-82. doi: 10.1038/sj.bjc.6605974. Epub 2010 Nov 23. Br J Cancer. 2010. PMID: 21102588 Free PMC article.